One of the most consistent changes in invasive solid tumors versus normal cells is a change in lysosomal characteristics, yet few drugs exploit this difference. WT35021 selectively kills tumor cells by targeting the lysosomal phenotype characteristic of invasive cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!